Efficacy and safety of infliximab in treating patients with ulcerative colitis: Experiences from a single medical center in southern China

Journal of Digestive Diseases

Volumn 15, Issue 9, 2014, Pages 483-490

  Zhou, You Lian ^a   Xie, Shan ^a   Wang, Pu ^a   Zhang, Ting ^a   Lin, Min Yi ^a   Tan, Jia Sheng ^a   Zhi, Fa Chao ^a   Jiang, Bo ^a   Chen, Ye ^a  

^a SOUTHERN MEDICAL UNIVERSITY   (China)

Author keywords

China; Drug related side effects and adverse reactions; Inflammatory bowel disease; Infliximab; Recurrence; Ulcerative colitis

Indexed keywords

GASTROINTESTINAL AGENT; INFLIXIMAB; MONOCLONAL ANTIBODY; NONSTEROID ANTIINFLAMMATORY AGENT;

ADOLESCENT; ADULT; AGED; COLITIS, ULCERATIVE; DRUG SCREENING; FEMALE; HUMAN; MALE; MIDDLE AGED; PROCEDURES; RECURRENT DISEASE; REMISSION; RETROSPECTIVE STUDY; RISK FACTOR; TREATMENT OUTCOME; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ANTIBODIES, MONOCLONAL; COLITIS, ULCERATIVE; DRUG EVALUATION; FEMALE; GASTROINTESTINAL AGENTS; HUMANS; MALE; MIDDLE AGED; RECURRENCE; REMISSION INDUCTION; RETROSPECTIVE STUDIES; RISK FACTORS; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84906817410     PISSN: 17512972     EISSN: 17512980     Source Type: Journal    
DOI: 10.1111/1751-2980.12161     Document Type: Article

References (37)

1. Turner D, Walsh CM, Steinhart AH, Griffiths AM. Response to corticosteroids in severe ulcerative colitis: a systematic review of the literature and a meta-regression. Clin Gastroenterol Hepatol 2007; 5: 103-110.
2. Faubion WA Jr, Loftus EV Jr, Harmsen WS, Zinsmeister AR, Sandborn WJ. The natural history of corticosteroid therapy for inflammatory bowel disease: a population-based study. Gastroenterology 2001; 121: 255-260.
3. Rutgeerts P, Sandborn WJ, Feagan BG etal. Infliximab for induction and maintenance therapy for ulcerative colitis. N Engl J Med 2005; 353: 2462-2476.
4. Gisbert JP, González-Lama Y, Maté J. Systematic review: infliximab therapy in ulcerative colitis. Aliment Pharmacol Ther 2007; 25: 19-37.
5. Ng SC, Tsoi KK, Kamm MA etal. Genetics of inflammatory bowel disease in Asia: systematic review and meta-analysis. Inflamm Bowel Dis 2012; 18: 1164-1176.
6. Jiang L, Xia B, Li J etal. Retrospective survey of 452 patients with inflammatory bowel disease in Wuhan city, central China. Inflamm Bowel Dis 2006; 12: 212-217.
7. Yun J, Xu CT, Pan BR. Epidemiology and gene markers of ulcerative colitis in the Chinese. World J Gastroenterol 2009; 15: 788-803.
8. Maini RN, Breedveld FC, Kalden JR etal. Therapeutic efficacy of multiple intravenous infusions of anti-tumor necrosis factor α monoclonal antibody combined with low-dose weekly methotrexate in rheumatoid arthritis. Arthritis Rheum 1998; 41: 1552-1563.
9. Brandt J, Sieper J, Braun J. Infliximab in the treatment of active and severe ankylosing spondylitis. Clin Exp Rheumatol 2002; 20: S106-110.
10. Lennard-Jones JE. Classification of inflammatory bowel disease. Scand J Gastroenterol Suppl 1989; 170: 2-6; discussion 16-9.
11. Satsangi J, Silverberg MS, Vermeire S, Colombel JF. The Montreal classification of inflammatory bowel disease: controversies, consensus, and implications. Gut 2006; 55: 749-753.
12. Stange EF, Travis SP, Vermeire S etal.; European Crohn's and Colitis Organisation (ECCO). European evidence-based consensus on the diagnosis and management of ulcerative colitis: Definitions and diagnosis. J Crohns Colitis 2008; 2: 1-23.
13. Lok AS, McMahon BJ. Chronic hepatitis B: update 2009. Hepatology 2009; 50: 661-662.
14. European Association for the Study of the Liver. EASL Clinical Practice Guidelines: Management of chronic hepatitis B virus infection. J Hepatol 2012; 57: 167-185.
15. Revello MG, Gerna G. Diagnosis and management of human cytomegalovirus infection in the mother, fetus, and newborn infant. Clin Microbiol Rev 2002; 15: 680-715.
16. Ljungman P, Griffiths P, Paya C. Definitions of cytomegalovirus infection and disease in transplant recipients. Clin Infect Dis 2002; 34: 1094-1097.
17. Okano M, Kawa K, Kimura H etal. Proposed guidelines for diagnosing chronic active Epstein-Barr virus infection. Am J Hematol 2005; 80: 64-69.
18. Łucejko M, Grzeszczuk A, Rogalska M, Flisiak R. Incidence of tuberculosis and mycobacteriosis among HIV-infected patients - clinical and epidemiological analysis of patients from north-eastern Poland. Pneumonol Alergol Pol 2013; 81: 502-510.
19. Kim J, Pai H, Seo MR, Kang JO. Epidemiology and clinical characteristics of Clostridium difficile infection in a Korean tertiary hospital. J Korean Med Sci 2011; 26: 1258-1264.
20. Colombel JF, Rutgeerts P, Reinisch W etal. Early mucosal healing with infliximab is associated with improved long-term clinical outcomes in ulcerative colitis. Gastroenterology 2011; 141: 1194-1201.
21. Lee KM, Jeen YT, Cho JY etal.; IBD study Group of Korean Association for the Study of Intestinal Diseases. Efficacy, safety, and predictors of response to infliximab therapy for ulcerative colitis: a Korean multicenter retrospective study. J Gastroenterol Hepatol 2013; 28: 1829-1833.
22. Su C, Salzberg BA, Lewis JD etal. Efficacy of anti-tumor necrosis factor therapy in patients with ulcerative colitis. Am J Gastroenterol 2002; 97: 2577-2584.
23. Ferrante M, Vermeire S, Fidder H etal. Long-term outcome after infliximab for refractory ulcerative colitis. J Crohns Colitis 2008; 2: 219-225.
24. Ferrante M, Vermeire S, Katsanos KH etal. Predictors of early response to infliximab in patients with ulcerative colitis. Inflamm Bowel Dis 2007; 13: 123-128.
25. Jürgens M, Laubender RP, Hartl F etal. Disease activity, ANCA, and IL23R genotype status determine early response to infliximab in patients with ulcerative colitis. Am J Gastroenterol 2010; 105: 1811-1819.
26. Seow CH, Newman A, Irwin SP, Steinhart AH, Silverberg MS, Greenberg GR. Trough serum infliximab: a predictive factor of clinical outcome for infliximab treatment in acute ulcerative colitis. Gut 2010; 59: 49-54.
27. Gonzalez-Lama Y, Fernandez-Blanco I, Lopez-SanRoman A etal.; Group for the Study of Inflammatory Bowel Diseases from Madrid. Open-label infliximab therapy in ulcerative colitis: a multicenter survey of results and predictors of response. Hepatogastroenterology 2008; 55: 1609-1614.
28. Ha C, Ullman TA, Siegel CA, Kornbluth A. Patients enrolled in randomized controlled trials do not represent the inflammatory bowel disease patient population. Clin Gastroenterol Hepatol 2012; 10: 1002-1007.
29. Bernstein CN, Fried M, Krabshuis JH etal. World Gastroenterology Organization Practice Guidelines for the diagnosis and management of IBD in 2010. Inflamm Bowel Dis 2010; 16: 112-124.
30. Caspersen S, Elkjaer M, Riis L etal. Infliximab for inflammatory bowel disease in Denmark 1999-2005: clinical outcome and follow-up evaluation of malignancy and mortality. Clin Gastroenterol Hepatol 2008; 6: 1212-1217.
31. Rudolph SJ, Weinberg DI, McCabe RP. Long-term durability of Crohn's disease treatment with infliximab. Dig Dis Sci 2008; 53: 1033-1041.
32. Schnitzler F, Fidder H, Ferrante M etal. Long-term outcome of treatment with infliximab in 614 patients with Crohn's disease: results from a single-centre cohort. Gut 2009; 58: 492-500.
33. Rutgeerts P, Diamond RH, Bala M etal. Scheduled maintenance treatment with infliximab is superior to episodic treatment for the healing of mucosal ulceration associated with Crohn's disease. Gastrointest Endosc 2006; 63: 433-442.
34. Rutgeerts P, Feagan BG, Lichtenstein GR etal. Comparison of scheduled and episodic treatment strategies of infliximab in Crohn's disease. Gastroenterology 2004; 126: 402-413.
35. Arijs I, Li K, Toedter G etal. Mucosal gene signatures to predict response to infliximab in patients with ulcerative colitis. Gut 2009; 58: 1612-1619.
36. Travis SP, Farrant JM, Ricketts C etal. Predicting outcome in severe ulcerative colitis. Gut 1996; 38: 905-910.
37. Ferrante M, Henckaerts L, Joossens M etal. New serological markers in inflammatory bowel disease are associated with complicated disease behaviour. Gut 2007; 56: 1394-1403.